Human TNFRSF25 antibody

Abstract

Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.

What is claimed is: 
     
       1. An anti-tumor necrosis factor superfamily receptor 25 (TNFRSF25) antibody, comprising:
 (a) a heavy chain comprising a heavy chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 4, a CDR2 sequence as set forth in SEQ ID NO: 6, and a CDR3 sequence as set forth in SEQ ID NO: 8; and 
 (b) a light chain comprising a light chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 11, a CDR2 sequence as set forth in SEQ ID NO: 13, and a CDR3 sequence as set forth in SEQ ID NO: 15. 
 
     
     
       2. The antibody of  claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1. 
     
     
       3. The antibody of  claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2. 
     
     
       4. The antibody of  claim 2 , wherein the heavy constant region of said antibody is selected from human IgG1, IgG2, IgG3, and IgG4. 
     
     
       5. The antibody of  claim 4 , wherein the heavy constant region is from human IgG4. 
     
     
       6. A method of treating a tumor in a subject, comprising administering to a subject the antibody of  claim 1 . 
     
     
       7. A composition comprising:
 (a) an anti-tumor necrosis factor superfamily receptor 25 (TNFRSF25) antibody, comprising:
 (i) a heavy chain comprising a heavy chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 4, a CDR2 sequence as set forth in SEQ ID NO: 6, and a CDR3 sequence as set forth in SEQ ID NO: 8; and 
 (ii) a light chain comprising a light chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 11, a CDR2 sequence as set forth in SEQ ID NO: 13, and a CDR3 sequence as set forth in SEQ ID NO: 15; and 
 
 (b) an additional agent for treating cancer. 
 
     
     
       8. A nucleic acid encoding an anti-TNFRSF25 antibody comprising:
 (a) a first nucleic acid sequence encoding a heavy chain comprising a heavy chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 4, a CDR2 sequence as set forth in SEQ ID NO: 6, and a CDR3 sequence as set forth in SEQ ID NO: 8; and 
 (b) a second nucleic acid sequence encoding a light chain comprising a light chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO:11, a CDR2 sequence as set forth in SEQ ID NO: 13, and a CDR3 sequence as set forth in SEQ ID NO: 15. 
 
     
     
       9. A host cell comprising the nucleic acid of  claim 8 . 
     
     
       10. A method of making an anti-TNFRSF25 antibody, comprising:
 a) providing the host cell of  claim 9 ; 
 b) culturing said host cell under conditions wherein said antibody is expressed; and 
 c) recovering said antibody from the host cell.